Aberrant immune checkpoint regulation, including PD-L1 expression dynamics and the upregulation of inhibitory receptors like TIGIT, TIM-3, and LAG-3, significantly contributes to ICI resistance in HCC. Here, TIGIT is linked to hepatocellular carcinoma.